Galantamine increases excitability of CA1 hippocampal pyramidal neurons

M. M. Oh, Wendy Wu, J. M. Power, J. F. Disterhoft

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Galantamine is a third generation cholinesterase inhibitor and an allosteric potentiating ligand of nicotinic acetylcholine receptors. It enhances learning in aging rabbits and alleviates cognitive deficits observed in patients with Alzheimer's disease. We examined galantamine's effect on CA1 neurons from hippocampal slices of young and aging rabbits using current-clamp, intracellular recording techniques. Galantamine (10-200μM) dose-dependently reduced the postburst afterhyperpolarization and the spike-frequency accommodation of CA1 neurons from both young and aging animals. These reductions were partially, but significantly, reversed by the addition of the muscarinic receptor antagonist, atropine (1μM), to the perfusate. In contrast, the nicotinic acetylcholine receptor antagonist, α-bungarotoxin (10nM), had no effect; i.e. α-bungarotoxin did not reverse the afterhyperpolarization and accommodation reductions. The allosteric potentiating ligand effect was examined by stimulating the Schaffer collateral and measuring the excitatory postsynaptic potentials for 30 min during bath application of galantamine. Galantamine (200μM) significantly enhanced the excitatory postsynaptic potential amplitude and area over time. These effects were blocked by 10nM α-bungarotoxin, supporting a role for galantamine as an allosteric potentiating ligand. We did not observe a facilitation of the excitatory postsynaptic potentials with 1μM galantamine. However, when the excitatory postsynaptic potential was pharmacologically isolated by adding 10μM gabazine (GABAA receptor antagonist) to the perfusate, 1μM galantamine potentiated the subthreshold excitatory postsynaptic potentials into action potentials. We propose that the learning enhancement observed in aging animals and the alleviation of cognitive deficits associated with Alzheimer's disease after galantamine treatment may in part be due to the enhanced function of both nicotinic and muscarinic excitatory transmission on hippocampal pyramidal neurons.

Original languageEnglish (US)
Pages (from-to)113-123
Number of pages11
JournalNeuroscience
Volume137
Issue number1
DOIs
StatePublished - 2006
Externally publishedYes

Fingerprint

Galantamine
Pyramidal Cells
Excitatory Postsynaptic Potentials
Bungarotoxins
Nicotinic Receptors
Ligands
Alzheimer Disease
Learning
Rabbits
GABA-A Receptor Antagonists
Neurons
Muscarinic Antagonists
Cholinesterase Inhibitors
Cholinergic Antagonists
Muscarinic Receptors
Baths
Atropine
Cholinergic Agents
Action Potentials
Hippocampus

Keywords

  • Afterhyperpolarization
  • Aging
  • Alzheimer's disease
  • Cholinesterase inhibitor
  • Muscarinic
  • Nicotinic

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Galantamine increases excitability of CA1 hippocampal pyramidal neurons. / Oh, M. M.; Wu, Wendy; Power, J. M.; Disterhoft, J. F.

In: Neuroscience, Vol. 137, No. 1, 2006, p. 113-123.

Research output: Contribution to journalArticle

Oh, M. M. ; Wu, Wendy ; Power, J. M. ; Disterhoft, J. F. / Galantamine increases excitability of CA1 hippocampal pyramidal neurons. In: Neuroscience. 2006 ; Vol. 137, No. 1. pp. 113-123.
@article{d6e33580f84b40299a9532fe6cf78540,
title = "Galantamine increases excitability of CA1 hippocampal pyramidal neurons",
abstract = "Galantamine is a third generation cholinesterase inhibitor and an allosteric potentiating ligand of nicotinic acetylcholine receptors. It enhances learning in aging rabbits and alleviates cognitive deficits observed in patients with Alzheimer's disease. We examined galantamine's effect on CA1 neurons from hippocampal slices of young and aging rabbits using current-clamp, intracellular recording techniques. Galantamine (10-200μM) dose-dependently reduced the postburst afterhyperpolarization and the spike-frequency accommodation of CA1 neurons from both young and aging animals. These reductions were partially, but significantly, reversed by the addition of the muscarinic receptor antagonist, atropine (1μM), to the perfusate. In contrast, the nicotinic acetylcholine receptor antagonist, α-bungarotoxin (10nM), had no effect; i.e. α-bungarotoxin did not reverse the afterhyperpolarization and accommodation reductions. The allosteric potentiating ligand effect was examined by stimulating the Schaffer collateral and measuring the excitatory postsynaptic potentials for 30 min during bath application of galantamine. Galantamine (200μM) significantly enhanced the excitatory postsynaptic potential amplitude and area over time. These effects were blocked by 10nM α-bungarotoxin, supporting a role for galantamine as an allosteric potentiating ligand. We did not observe a facilitation of the excitatory postsynaptic potentials with 1μM galantamine. However, when the excitatory postsynaptic potential was pharmacologically isolated by adding 10μM gabazine (GABAA receptor antagonist) to the perfusate, 1μM galantamine potentiated the subthreshold excitatory postsynaptic potentials into action potentials. We propose that the learning enhancement observed in aging animals and the alleviation of cognitive deficits associated with Alzheimer's disease after galantamine treatment may in part be due to the enhanced function of both nicotinic and muscarinic excitatory transmission on hippocampal pyramidal neurons.",
keywords = "Afterhyperpolarization, Aging, Alzheimer's disease, Cholinesterase inhibitor, Muscarinic, Nicotinic",
author = "Oh, {M. M.} and Wendy Wu and Power, {J. M.} and Disterhoft, {J. F.}",
year = "2006",
doi = "10.1016/j.neuroscience.2005.08.063",
language = "English (US)",
volume = "137",
pages = "113--123",
journal = "Neuroscience",
issn = "0306-4522",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Galantamine increases excitability of CA1 hippocampal pyramidal neurons

AU - Oh, M. M.

AU - Wu, Wendy

AU - Power, J. M.

AU - Disterhoft, J. F.

PY - 2006

Y1 - 2006

N2 - Galantamine is a third generation cholinesterase inhibitor and an allosteric potentiating ligand of nicotinic acetylcholine receptors. It enhances learning in aging rabbits and alleviates cognitive deficits observed in patients with Alzheimer's disease. We examined galantamine's effect on CA1 neurons from hippocampal slices of young and aging rabbits using current-clamp, intracellular recording techniques. Galantamine (10-200μM) dose-dependently reduced the postburst afterhyperpolarization and the spike-frequency accommodation of CA1 neurons from both young and aging animals. These reductions were partially, but significantly, reversed by the addition of the muscarinic receptor antagonist, atropine (1μM), to the perfusate. In contrast, the nicotinic acetylcholine receptor antagonist, α-bungarotoxin (10nM), had no effect; i.e. α-bungarotoxin did not reverse the afterhyperpolarization and accommodation reductions. The allosteric potentiating ligand effect was examined by stimulating the Schaffer collateral and measuring the excitatory postsynaptic potentials for 30 min during bath application of galantamine. Galantamine (200μM) significantly enhanced the excitatory postsynaptic potential amplitude and area over time. These effects were blocked by 10nM α-bungarotoxin, supporting a role for galantamine as an allosteric potentiating ligand. We did not observe a facilitation of the excitatory postsynaptic potentials with 1μM galantamine. However, when the excitatory postsynaptic potential was pharmacologically isolated by adding 10μM gabazine (GABAA receptor antagonist) to the perfusate, 1μM galantamine potentiated the subthreshold excitatory postsynaptic potentials into action potentials. We propose that the learning enhancement observed in aging animals and the alleviation of cognitive deficits associated with Alzheimer's disease after galantamine treatment may in part be due to the enhanced function of both nicotinic and muscarinic excitatory transmission on hippocampal pyramidal neurons.

AB - Galantamine is a third generation cholinesterase inhibitor and an allosteric potentiating ligand of nicotinic acetylcholine receptors. It enhances learning in aging rabbits and alleviates cognitive deficits observed in patients with Alzheimer's disease. We examined galantamine's effect on CA1 neurons from hippocampal slices of young and aging rabbits using current-clamp, intracellular recording techniques. Galantamine (10-200μM) dose-dependently reduced the postburst afterhyperpolarization and the spike-frequency accommodation of CA1 neurons from both young and aging animals. These reductions were partially, but significantly, reversed by the addition of the muscarinic receptor antagonist, atropine (1μM), to the perfusate. In contrast, the nicotinic acetylcholine receptor antagonist, α-bungarotoxin (10nM), had no effect; i.e. α-bungarotoxin did not reverse the afterhyperpolarization and accommodation reductions. The allosteric potentiating ligand effect was examined by stimulating the Schaffer collateral and measuring the excitatory postsynaptic potentials for 30 min during bath application of galantamine. Galantamine (200μM) significantly enhanced the excitatory postsynaptic potential amplitude and area over time. These effects were blocked by 10nM α-bungarotoxin, supporting a role for galantamine as an allosteric potentiating ligand. We did not observe a facilitation of the excitatory postsynaptic potentials with 1μM galantamine. However, when the excitatory postsynaptic potential was pharmacologically isolated by adding 10μM gabazine (GABAA receptor antagonist) to the perfusate, 1μM galantamine potentiated the subthreshold excitatory postsynaptic potentials into action potentials. We propose that the learning enhancement observed in aging animals and the alleviation of cognitive deficits associated with Alzheimer's disease after galantamine treatment may in part be due to the enhanced function of both nicotinic and muscarinic excitatory transmission on hippocampal pyramidal neurons.

KW - Afterhyperpolarization

KW - Aging

KW - Alzheimer's disease

KW - Cholinesterase inhibitor

KW - Muscarinic

KW - Nicotinic

UR - http://www.scopus.com/inward/record.url?scp=29744467225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29744467225&partnerID=8YFLogxK

U2 - 10.1016/j.neuroscience.2005.08.063

DO - 10.1016/j.neuroscience.2005.08.063

M3 - Article

C2 - 16242849

AN - SCOPUS:29744467225

VL - 137

SP - 113

EP - 123

JO - Neuroscience

JF - Neuroscience

SN - 0306-4522

IS - 1

ER -